Absent T Lymphocytes

Search Trials
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Status:
Recruiting
Last Changed:
Nov 9, 2021
First Changed:
Sep 29, 2020
Disease(s):
Peripheral T-cell Lymphoma
Intervention(s):
brentuximab vedotincyclophosphamidedoxorubicinprednisone
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
Status:
Terminated
Last Changed:
Aug 18, 2009
First Changed:
Mar 23, 2006
Disease(s):
Leukemia, Myeloid
Intervention(s):
T-cell and B-cell depletion
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Status:
Recruiting
Last Changed:
Nov 1, 2021
First Changed:
Nov 8, 2016
Disease(s):
Breast Adenocarcinoma
Intervention(s):
DoxorubicinCyclophosphamidePaclitaxelCarboplatinDecitabinePembrolizumab
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Status:
Unknown status
Last Changed:
Dec 5, 2016
First Changed:
Oct 27, 2015
Disease(s):
Hepatocellular Carcinoma
Intervention(s):
anti-MUC1 CAR T Cells
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Status:
Recruiting
Last Changed:
Nov 4, 2021
First Changed:
Mar 11, 2016
Disease(s):
Hematopoietic and Lymphoid Cell Neoplasm
Intervention(s):
Laboratory Biomarker AnalysisROR1 CAR-specific Autologous T-Lymphocytes

Connect. Empower. Inspire.